Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 1/20 | 0.48 |
| ▸ | CCNT1 | O60563 | 14/20 | 0.46 |
| ▸ | CDK9 | P50750 | 14/20 | 0.46 |
| ▸ | HTR6 | P50406 | 3/20 | 0.45 |
| ▸ | HTR7 | P34969 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | BCL9 | O00512 | 1/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4562535 | 0.79 | CCNT1 (0.50) | QDPRCCNT1CDK9HTR6HTR7 | |
| SCHEMBL30388286 | 0.78 | HTR6 (0.53) | QDPRCCNT1CDK9HTR6HTR7 | |
| SCHEMBL15227112 | 0.77 | KDM1A (0.46) | CCNT1CDK9HTR6HTR7HTR2A | |
| SCHEMBL5020013 | 0.77 | CCNT1 (0.48) | QDPRCCNT1CDK9HTR6HTR7 | |
| SCHEMBL31652100 | 0.74 | ALK (0.49) | QDPRCCNT1CDK9TGFBR1ACVR1 | |
| SCHEMBL16874849 | 0.73 | QDPR (0.66) | QDPRCCNT1CDK9HTR2CTGFBR1 | |
| SCHEMBL3547373 | 0.73 | CCNT1 (0.61) | QDPRCCNT1CDK9 | |
| SCHEMBL27553177 | 0.73 | QDPR (0.70) | QDPRCCNT1CDK9HTR2CBCL9 | |
| Hydrochloric Acid SCHEMBL979625 | 0.72 | QDPR (0.64) | QDPRCCNT1CDK9HTR2CTGFBR1 | |
| SCHEMBL31701454 | 0.71 | CCNT1 (0.41) | QDPRCCNT1CDK9HTR6HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2013-09-05 | — | — | US | disclosed |
| WO-2012062752-A1 | RADIOLABELLED mGLuR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | GRM2, GRM3, GRM1 | QDPR 2833/4885CCNT1 3537/4885CDK9 2257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.